SAN FRANCISCO and MIAMI BEACH, Fla., Sept. 3, 2014 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be featured in a presentation at the American Society of Clinical Oncology's (ASCO) Breast Cancer Symposium 2014. The data will be presented by Biscayne's Medical Director, Norman Block, MD, who is also Clinical Director of the Endocrine, Polypeptide and Cancer Institute at the Veterans Affairs Medical Center in Miami and the L. Austin Weeks Family Professor of Urologic Research at the University of Miami Miller School of Medicine.
Scientists have long known that GHRH, which is made in the brain, releases growth hormone to manage growth and tissue repair in nearby cells. Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate, discovered that other cells throughout the body, including cancer cells, also have receptors for GHRH. Cancer cells contain GHRH receptors and also produce the GHRH hormone, thereby fueling their own growth. Biscayne Pharmaceuticals has licensed rights to Dr. Schally's GHRH discoveries and is developing GHRH antagonists that inhibit tumor growth by binding to and blocking the activity of the GHRH receptors on cancer cells.
Much of the earlier work on GHRH and cancer has been conducted in preclinical models. In the Breast Cancer Symposium 2014 poster presentation1, Dr. Block and his colleagues present data on GHRH using specimens from breast cancer patients. They conclude that the majority of breast cancers, including both primary and metastatic tumors, are GHRH-receptor positive, confirming the validity of GHRH as a potential therapeutic target for new breast
|SOURCE Biscayne Pharmaceuticals, Inc.|
Copyright©2014 PR Newswire.
All rights reserved